Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.15 USD | +3.70% | -3.15% | -30.29% |
Financials (USD)
Sales 2022 | 25.9M | Sales 2023 | 42.81M | Capitalization | 17.99M |
---|---|---|---|---|---|
Net income 2022 | -33M | Net income 2023 | -24M | EV / Sales 2022 | 1.21 x |
Net cash position 2022 | 46.07M | Net cash position 2023 | 26.37M | EV / Sales 2023 | -0.2 x |
P/E ratio 2022 |
-2.32
x | P/E ratio 2023 |
-0.67
x | Employees | 48 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 93.03% |
Latest transcript on Pieris Pharmaceuticals, Inc.
1 day | +3.70% | ||
1 week | -3.15% | ||
1 month | -13.10% | ||
3 months | -26.66% | ||
6 months | -38.97% | ||
Current year | -30.29% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Yoder
CEO | Chief Executive Officer | 48 | 09-12-31 |
Thomas Bures
DFI | Director of Finance/CFO | 49 | 17-11-30 |
Kayti Aviano
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 16-09-19 | |
James Geraghty
CHM | Chairman | 69 | 17-05-21 |
Michael Richman
BRD | Director/Board Member | 63 | 14-12-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 10.15 | +3.70% | 4,555 |
24-05-30 | 9.788 | +1.95% | 2,340 |
24-05-29 | 9.6 | -1.54% | 7,970 |
24-05-28 | 9.75 | -6.96% | 12,939 |
24-05-24 | 10.48 | -0.10% | 1,902 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.29% | 13.4M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- PIRS Stock